Investor Relations

-- Presentations Detail Twist’s Methylation Solution, a Cost-Effective Alternative to Single Nucleotide Polymorphism (SNP) Microarray Technology and Data on the Infectious Disease Product Line --

SAN FRANCISCO--(BUSINESS WIRE)--Oct. 29, 2020-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the presentation of new customer and company data generated using the Twist Bioscience target enrichment and library preparation products for next-generation sequencing (NGS).

“The data presented at ASHG highlight the diverse applications of our NGS target enrichment technology which can be applied to consumer genomics, cancer detection, rare disease research, as well as tracking viral evolution of infectious diseases,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “We remain focused on delivering optimal products for our customers to advance research for the most pressing public health issues including COVID-19, while at the same time continuing to develop synthetic DNA based solutions to improve health and sustainability.”

In addition to customer presentations from Harvard Medical School and Sema4, Twist Bioscience scientists will be presenting posters on the following topics:

• Poster #3568: Targeted Sequencing-based Genotyping as a Competitive Alternative to Genotyping Arrays. In this poster, a case study showcasing the design of a Twist Custom Target Capture Panel for the identification of hundreds of thousands of markers by NGS. In this groundbreaking poster, data demonstrate that Twist can apply its Custom Panel design algorithms to generate an exceptionally large target enrichment panel with more than 240,000 single nucleotide polymorphism (SNP) with exceptional and consistent performance. These data show that Twist is able to produce a unified workflow to merge genotyping with exome sequencing, leading to considerable cost savings while maintaining high-quality data.
• Poster #2445: Tunability and Optimization Using the Twist Fast Hybridization Target Enrichment System for DNA Methylation Sequencing. This poster highlights Twist’s Targeted Methylation Sequencing Solution and a novel and innovative way to generate libraries used for methylation detection. While genetic sequencing has allowed the ability to link sequence with a number of disease states, other factors, including DNA methylation modifications on adenines and cytosines, can affect gene expression through epigenetic processes. Twist’s solution can be used in combination with several different sized custom designed DNA methylation panels and tuned to best fit timelines and preferred final picard metrics while differentiating original methylation states.
• Poster #3293: A Target Enrichment Approach for Identifying Infectious Disease. In this poster, we demonstrate Twist's target enrichment systems as a sensitive and informative approach combining library preparation and 30 minute Fast Hybridization for detecting viral agents that can be RNA or DNA as well as single- or double-stranded. The data show that our SARS-CoV-2 Research Panel can detect the virus with as few as 10 copies of SARS-CoV-2 genome. Extending our results beyond single infections, the data demonstrate that Twist’s Respiratory Virus Research Panel simultaneously detects multiple viral agents which can then be sequenced with excellent coverage in a model of co-infection.

The posters will be available through the resources section of the Twist Bioscience website.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2020. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201029005467/en/

Investor Contact:
Argot Partners
Maeve Conneighton
212-600-1902
maeve@argotpartners.com

Media Contact:
Angela Bitting
925- 202-6211
media@twistbioscience.com

Source: Twist Bioscience Corporation